GlassScriptPhysician profile
Giancarlo Acosta
NPI 1609155969
$9,867.23
in general payments reported to CMS, 2019-2025
32 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $225 · 2021: $1,374 · 2022: $1,569 · 2023: $1,969 · 2024: $1,863 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,462 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,462.03 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,128.35 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $1,102.54 | 2019-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $778.97 | 2019-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $634.10 | 2021-2024 | Uptravi, Opsumit |
| Pfizer INC. | $573.28 | 2021-2025 | |
| Abbott Laboratories | $521.35 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| E.R. Squibb & Sons, L.L.C. | $519.71 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $469.35 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $413.71 | 2021-2025 | |
| Novo Nordisk INC | $339.13 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lexicon Pharmaceuticals, INC. | $308.25 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.05 | 2021-2025 | Jardiance |
| Scpharmaceuticals INC. | $288.15 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $286.39 | 2021-2025 | Amvuttra, Onpattro |
| Amgen INC. | $248.85 | 2019-2023 | Repatha |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $243.78 | 2019-2025 | Optimizer, Optimizer |
| United Therapeutics Corporation | $234.52 | 2021-2025 | Tyvaso, Orenitram, Remodulin |
| Kestra Medical Technology Services, INC. | $217.89 | 2022-2025 | Assure Wcd |
| Daiichi Sankyo INC. | $215.10 | 2021-2024 | Injectafer |
| Cvrx, INC. | $185.99 | 2021-2025 | Barostim Neo System |
| Abiomed | $171.16 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $165.98 | 2022-2024 | Xarelto |
| Atricure, INC. | $128.52 | 2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax |
| Astellas Pharma US INC | $81.83 | 2020-2021 | |
| Boston Scientific Corporation | $80.03 | 2019-2024 | Watchman Flx, Watchman Access System |
| Philips North America LLC | $55.44 | 2022-2024 | (5044) Mcot |
| W. L. Gore & Associates, INC. | $38.49 | 2021 | |
| Chiesi USA, INC. | $32.05 | 2020-2021 | |
| Medtronic, INC. | $29.69 | 2021 | |
| Innovation Technologies INC | $26.27 | 2025 | Irrisept |
| Medtronic Vascular, INC. | $24.74 | 2019-2020 | |
| Lilly USA, LLC | $16.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giancarlo Acosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.